Recent progress in pancreatic islet cell therapy

Abstract Human pluripotent stem cells (PSCs), including human embryonic stem cells and induced pluripotent stem cells, are promising cell sources in regenerating pancreatic islets through in vitro directed differentiation. Recent progress in this research field has made it possible to generate gluco...

Full description

Bibliographic Details
Main Authors: Erinn Zixuan Sim, Nobuaki Shiraki, Shoen Kume
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Inflammation and Regeneration
Subjects:
Online Access:https://doi.org/10.1186/s41232-020-00152-5
id doaj-2d24d0ea6c9d4d12bccda39aaf9b3953
record_format Article
spelling doaj-2d24d0ea6c9d4d12bccda39aaf9b39532021-01-10T12:52:06ZengBMCInflammation and Regeneration1880-81902021-01-0141111010.1186/s41232-020-00152-5Recent progress in pancreatic islet cell therapyErinn Zixuan Sim0Nobuaki Shiraki1Shoen Kume2School of Life Science and Technology, Tokyo Institute of TechnologySchool of Life Science and Technology, Tokyo Institute of TechnologySchool of Life Science and Technology, Tokyo Institute of TechnologyAbstract Human pluripotent stem cells (PSCs), including human embryonic stem cells and induced pluripotent stem cells, are promising cell sources in regenerating pancreatic islets through in vitro directed differentiation. Recent progress in this research field has made it possible to generate glucose-responsive pancreatic islet cells from PSCs. Single-cell RNA sequencing techniques have been applied to analyze PSC-derived endocrine beta-cells, which are then compared with human islets. This has led to the identification of novel signaling pathways and molecules involved in lineage commitment during pancreatic differentiation and maturation processes. Single-cell transcriptomics are also used to construct a detailed map of in vivo endocrine differentiation of developing mouse embryos to study pancreatic islet development. Mimicking those occurring in vivo, it was reported that differentiating PSCs can generate similar islet cell structures, while metabolomics analysis highlighted key components involved in PSC-derived pancreatic islet cell function, providing information for the improvement of in vitro pancreatic maturation procedures. In addition, cell transplantation into diabetic animal models, together with the cell delivery system, is studied to ensure the therapeutic potentials of PSC-derived pancreatic islet cells. Combined with gene-editing technology, the engineered mutation-corrected PSC lines originated from diabetes patients could be differentiated into functional pancreatic islet cells, suggesting possible autologous cell therapy in the future. These PSC-derived pancreatic islet cells are a potential tool for studies of disease modeling and drug testing. Herein, we outlined the directed differentiation procedures of PSC-derived pancreatic islet cells, novel findings through transcriptome and metabolome studies, and recent progress in disease modeling.https://doi.org/10.1186/s41232-020-00152-5Pluripotent stem cellsDirected differentiationPancreatic isletsTransplantationDisease modeling
collection DOAJ
language English
format Article
sources DOAJ
author Erinn Zixuan Sim
Nobuaki Shiraki
Shoen Kume
spellingShingle Erinn Zixuan Sim
Nobuaki Shiraki
Shoen Kume
Recent progress in pancreatic islet cell therapy
Inflammation and Regeneration
Pluripotent stem cells
Directed differentiation
Pancreatic islets
Transplantation
Disease modeling
author_facet Erinn Zixuan Sim
Nobuaki Shiraki
Shoen Kume
author_sort Erinn Zixuan Sim
title Recent progress in pancreatic islet cell therapy
title_short Recent progress in pancreatic islet cell therapy
title_full Recent progress in pancreatic islet cell therapy
title_fullStr Recent progress in pancreatic islet cell therapy
title_full_unstemmed Recent progress in pancreatic islet cell therapy
title_sort recent progress in pancreatic islet cell therapy
publisher BMC
series Inflammation and Regeneration
issn 1880-8190
publishDate 2021-01-01
description Abstract Human pluripotent stem cells (PSCs), including human embryonic stem cells and induced pluripotent stem cells, are promising cell sources in regenerating pancreatic islets through in vitro directed differentiation. Recent progress in this research field has made it possible to generate glucose-responsive pancreatic islet cells from PSCs. Single-cell RNA sequencing techniques have been applied to analyze PSC-derived endocrine beta-cells, which are then compared with human islets. This has led to the identification of novel signaling pathways and molecules involved in lineage commitment during pancreatic differentiation and maturation processes. Single-cell transcriptomics are also used to construct a detailed map of in vivo endocrine differentiation of developing mouse embryos to study pancreatic islet development. Mimicking those occurring in vivo, it was reported that differentiating PSCs can generate similar islet cell structures, while metabolomics analysis highlighted key components involved in PSC-derived pancreatic islet cell function, providing information for the improvement of in vitro pancreatic maturation procedures. In addition, cell transplantation into diabetic animal models, together with the cell delivery system, is studied to ensure the therapeutic potentials of PSC-derived pancreatic islet cells. Combined with gene-editing technology, the engineered mutation-corrected PSC lines originated from diabetes patients could be differentiated into functional pancreatic islet cells, suggesting possible autologous cell therapy in the future. These PSC-derived pancreatic islet cells are a potential tool for studies of disease modeling and drug testing. Herein, we outlined the directed differentiation procedures of PSC-derived pancreatic islet cells, novel findings through transcriptome and metabolome studies, and recent progress in disease modeling.
topic Pluripotent stem cells
Directed differentiation
Pancreatic islets
Transplantation
Disease modeling
url https://doi.org/10.1186/s41232-020-00152-5
work_keys_str_mv AT erinnzixuansim recentprogressinpancreaticisletcelltherapy
AT nobuakishiraki recentprogressinpancreaticisletcelltherapy
AT shoenkume recentprogressinpancreaticisletcelltherapy
_version_ 1724342187798298624